Amedeo Smart

Free Medical Literature Service

 

Amedeo

Obesity
  Free Subscription

Articles published in
Lancet
    December 2026
  1. HAY SI, Ng M, Gakidou E, Murray CJL, et al
    The need for metabolic health stratification in global obesity forecasts - Authors' reply.
    Lancet. 2026;406:2923-2924.
    >> Share

  2. FAUCHIER L, Guglieri M, Fauchier G
    The need for metabolic health stratification in global obesity forecasts.
    Lancet. 2026;406:2923.
    >> Share

  3. CHOW EW, Chow E
    Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity.
    Lancet. 2026;406:2866-2868.
    >> Share

  4. MUSKIET MHA, Nardone M, Rensen PCN, Cherney DZI, et al
    Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
    Lancet. 2026;406:2980-2983.
    >> Share

    March 2026
  5. THE LANCET
    Making treatment for obesity more equitable.
    Lancet. 2026;407:1119.
    >> Share

  6. COUSINS S
    The boom in counterfeit obesity drugs.
    Lancet. 2026 Mar 5:S0140-6736(26)00461-7. doi: 10.1016/S0140-6736(26)00461.
    >> Share

    February 2026
  7. NYBERG ST, Frank P, Ahmadi-Abhari S, Pentti J, et al
    Adult obesity and risk of severe infections: a multicohort study with global burden estimates.
    Lancet. 2026 Feb 9:S0140-6736(25)02474-2. doi: 10.1016/S0140-6736(25)02474.
    >> Share

  8. SORENSEN TIA, Osler M
    Mutually reinforced burdens of obesity and infections.
    Lancet. 2026 Feb 9:S0140-6736(25)02605-4. doi: 10.1016/S0140-6736(25)02605.
    >> Share

    January 2026
  9. NAUCK MA, Tuttle KR, Tschop MH, Bluher M, et al
    Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
    Lancet. 2026 Jan 14:S0140-6736(25)02105-1. doi: 10.1016/S0140-6736(25)02105.
    >> Share

    November 2025
  10. HORN DB, Ryan DH, Kis SG, Alves B, et al
    Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
    Lancet. 2025 Nov 20:S0140-6736(25)02165-8. doi: 10.1016/S0140-6736(25)02165.
    >> Share

  11. BILLINGS LK, Hsia S, Bays H, Tidemann-Miller B, et al
    Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet. 2025 Nov 6:S0140-6736(25)02155-5. doi: 10.1016/S0140-6736(25)02155.
    >> Share

    October 2025
  12. DEANFIELD J, Lincoff AM, Kahn SE, Emerson SS, et al
    Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
    Lancet. 2025 Oct 22:S0140-6736(25)01375-3. doi: 10.1016/S0140-6736(25)01375.
    >> Share

    September 2025
  13. THE LANCET
    Childhood obesity: a global health crisis.
    Lancet. 2025;406:1193.
    >> Share

  14. HUNTER KE, Nguyen D, Libesman S, Williams JG, et al
    Parent-focused behavioural interventions for the prevention of early childhood obesity (TOPCHILD): a systematic review and individual participant data meta-analysis.
    Lancet. 2025 Sep 10:S0140-6736(25)01144-4. doi: 10.1016/S0140-6736(25)01144.
    >> Share

    August 2025
  15. ROBERT M, Poghosyan T, Romain-Scelle N, Czernichow S, et al
    Efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy versus Roux-en-Y gastric bypass in France (SADISLEEVE): results of a randomised, open-label, superiority trial at 2 years of follow-up.
    Lancet. 2025;406:846-859.
    >> Share

  16. ELLS LJ, Homer C, Matu J, Aswani D, et al
    Compassionate child obesity care within a stigmatising society.
    Lancet. 2025;406:444.
    >> Share

    July 2025
  17. DAHL K, Toubro S, Dey S, Duque do Vale R, et al
    Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
    Lancet. 2025;406:149-162.
    >> Share

  18. GASIOREK A, Heydorn A, Gabery S, Hjerpsted JB, et al
    Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
    Lancet. 2025;406:135-148.
    >> Share

    June 2025
  19. KHOO B, Tan TM
    GLP-1 and amylin receptor multiagonism with amycretin for obesity management.
    Lancet. 2025 Jun 20:S0140-6736(25)01250-4. doi: 10.1016/S0140-6736(25)01250.
    >> Share

  20. LUK A, Wild SH, Jones S, Anjana RM, et al
    Early-onset type 2 diabetes: the next major diabetes transition.
    Lancet. 2025 Jun 20:S0140-6736(25)00830-X. doi: 10.1016/S0140-6736(25)00830.
    >> Share

    February 2025

  21. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
    Lancet. 2025 Feb 28:S0140-6736(25)00355-1. doi: 10.1016/S0140-6736(25)00355.
    >> Share


  22. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
    Lancet. 2025 Feb 28:S0140-6736(25)00397-6. doi: 10.1016/S0140-6736(25)00397.
    >> Share

  23. SORENSEN TIA
    Forecasting the global obesity epidemic through 2050.
    Lancet. 2025 Feb 28:S0140-6736(25)00260-0. doi: 10.1016/S0140-6736(25)00260.
    >> Share

    January 2025
  24. HORTON R
    Offline: Making obesity matter.
    Lancet. 2025;405:284.
    >> Share

  25. KLOPPENBURG M, Namane M, Cicuttini F
    Osteoarthritis.
    Lancet. 2025;405:71-85.
    >> Share

    November 2024
  26. KIRBY T
    Brazil considers obesity discrimination law.
    Lancet. 2024;404:1912-1913.
    >> Share

  27. SEBERT S
    The obesity crisis in the USA: why are there no signs of plateauing yet?
    Lancet. 2024 Nov 12:S0140-6736(24)02467-X. doi: 10.1016/S0140-6736(24)02467.
    >> Share


  28. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050.
    Lancet. 2024 Nov 12:S0140-6736(24)01548-4. doi: 10.1016/S0140-6736(24)01548.
    >> Share

    October 2024
  29. EZZATI M, Zhou B, Bennett JE, Phelps NH, et al
    Assessing worldwide trends of underweight and obesity - Authors' reply.
    Lancet. 2024;404:1644.
    >> Share

  30. BOMBAK A, Riediger N
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1643.
    >> Share

  31. CHRISTENSEN DL, Bygbjerg IC
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1642.
    >> Share

  32. CZERNICHOW S, Ziegler O, Clement K, Coupaye M, et al
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1642-1643.
    >> Share

  33. VAN STEIJVOORT E, Borry P
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1641-1642.
    >> Share

    August 2024

  34. General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7.5 million participants.
    Lancet. 2024;404:851-863.
    >> Share

  35. NASIR K
    Embracing the duality of BMI and central adiposity.
    Lancet. 2024;404:824-825.
    >> Share

  36. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    >> Share

  37. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    >> Share

  38. LINGVAY I, Cohen RV, Roux CWL, Sumithran P, et al
    Obesity in adults.
    Lancet. 2024 Aug 16:S0140-6736(24)01210-8. doi: 10.1016/S0140-6736(24)01210.
    >> Share

    May 2024
  39. MORIN-PAPUNEN L
    Bariatric surgery in women with PCOS and obesity.
    Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811.
    >> Share

  40. SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al
    Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
    Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538.
    >> Share

    April 2024
  41. THE LANCET EDITORS
    Retraction and republication-Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2024;403:1321.
    >> Share

  42. SHI Q, Wang Y, Hao Q, Vandvik PO, et al
    Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2024;403:e21-e31.
    >> Share

  43. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
    Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
    >> Share

  44. DONAL E, L'Official G, Istratoaie S
    Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
    Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
    >> Share

    March 2024
  45. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
    Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
    Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
    >> Share

  46. GAILLARD R
    Optimising gestational weight gain among pregnant women with obesity.
    Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
    >> Share

    February 2024
  47. TUMAS N, Lopez SR
    Double burden of underweight and obesity: insights from new global evidence.
    Lancet. 2024 Feb 29:S0140-6736(24)00051-5. doi: 10.1016/S0140-6736(24)00051.
    >> Share


  48. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.
    Lancet. 2024 Feb 29:S0140-6736(23)02750-2. doi: 10.1016/S0140-6736(23)02750.
    >> Share

  49. CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al
    Heart failure with preserved ejection fraction: everything the clinician needs to know.
    Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756.
    >> Share

    January 2024
  50. THE LANCET
    Treating obesity and diabetes: drugs alone are not enough.
    Lancet. 2024;403:1.
    >> Share

    December 2023
  51. DANIELS JP
    Colombia introduces junk food tax.
    Lancet. 2023;402:2062.
    >> Share

    November 2023
  52. ZOU M, Northstone K, Leary S
    Causal effects of later-eating rhythm on adiposity in children through the comparison of two cohorts in the UK and China: a cross-cohort study.
    Lancet. 2023;402 Suppl 1:S99.
    >> Share

  53. ALRUBAIAN F, Mulla Z
    Governments policy measures to address obesity among adults: a scoping review of the global evidence.
    Lancet. 2023;402 Suppl 1:S20.
    >> Share

  54. CISNEROS AB, Headings R, Wells R, Reynolds C, et al
    Understanding the use of media analysis in public health research through food tax debates (HEALTHEI Project): a scoping review.
    Lancet. 2023;402 Suppl 1:S9.
    >> Share

  55. SPAVIN A, Moore A, Lunn J, Tucker F, et al
    Reflecting on parental insights into healthy lifestyles: a qualitative study.
    Lancet. 2023;402 Suppl 1:S85.
    >> Share

  56. CHEN S, Kuper H
    Tracing the temporal trends of modifiable risk factors in dementia: insights from the English Longitudinal Study of Ageing (2004-2019).
    Lancet. 2023;402 Suppl 1:S34.
    >> Share

  57. WALSH S, Wallace L, Kuhn I, Mytton O, et al
    Population-level interventions for the primary prevention of dementia: a complex evidence review.
    Lancet. 2023;402 Suppl 1:S13.
    >> Share

    October 2023
  58. KOTANI T, Tano S
    Long-term effects of gestational weight gain on mortality.
    Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837.
    >> Share

  59. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    >> Share

    September 2023
  60. SUMITHRAN P, Finucane FM, Cohen RV
    Obesity drug shortages are symptomatic of wider malaise.
    Lancet. 2023 Sep 29:S0140-6736(23)01963-3. doi: 10.1016/S0140-6736(23)01963.
    >> Share

    June 2023
  61. GARVEY WT, Frias JP, Jastreboff AM, le Roux CW, et al
    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi: 10.1016/S0140-6736(23)01200.
    >> Share

  62. APOVIAN CM, McDonnell ME
    CagriSema and the link between obesity and type 2 diabetes.
    Lancet. 2023 Jun 23:S0140-6736(23)01291-6. doi: 10.1016/S0140-6736(23)01291.
    >> Share

  63. KNOP FK, Aroda VR, do Vale RD, Holst-Hansen T, et al
    Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01185-6. doi: 10.1016/S0140-6736(23)01185.
    >> Share

  64. FALLOWS E, Ells L, Anand V
    Semaglutide and the future of obesity care in the UK.
    Lancet. 2023 Jun 5:S0140-6736(23)01083-8. doi: 10.1016/S0140-6736(23)01083.
    >> Share

    May 2023
  65. SKYLE D
    Fatima Cody Stanford: changing the narrative on obesity.
    Lancet. 2023;401:1644.
    >> Share

    April 2023
  66. MAHGOUB S, Newsome PN
    Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis.
    Lancet. 2023 Apr 20:S0140-6736(23)00773-0. doi: 10.1016/S0140-6736(23)00773.
    >> Share

  67. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016